JPMorgan Downgrades Eidos Therapeutics (EIDX) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. CSCO
2. CBRS
3. COHR
4. SPY
5. NVDA
6. WYFI
7. STUB
8. EAT
9. BTGO
10. GO

January 23, 2019 5:10 AM EST
Get Alerts EIDX Hot Sheet
Price: $122.21 --0%

Rating Summary:
    1 Buy, 8 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE

JPMorgan analyst Anupam Rama downgraded Eidos Therapeutics (NASDAQ: EIDX) from Overweight to Neutral with a price target of $29.00.

The analyst adjusts recommendations for US SMid names following the recent Healthcare Conference.

For an analyst ratings summary and ratings history on Eidos Therapeutics click here. For more ratings news on Eidos Therapeutics click here.

Shares of Eidos Therapeutics closed at $12.71 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Downgrades

Related Entities

JPMorgan